Surface Oncology Inc. (NASDAQ:SURF) shares traded lower over the last trading session, losing -14.56% on 12/17/20. The shares fell to a low of $8.38 before closing at $8.51. Intraday shares traded counted 3.49 million, which was -280.36% lower than its 30-day average trading volume of 918.31K. SURF’s previous close was $9.96 while the outstanding shares total 40.01M. The firm stock’s Relative Strength Index (RSI) is 47.63, with weekly volatility at 12.64% and ATR at 0.86. The SURF stock’s 52-week price range has touched low of $1.38 and a $10.74 high.
Investors have identified the Biotechnology company Surface Oncology Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $353.85 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Surface Oncology Inc. (SURF) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 107.6 million total, with 13.55 million as their total liabilities.
SURF were able to record -42.33 million as free cash flow during the Q3 2020 quarter of the year, this saw their quarterly net cash flow reduce by 52.71 million. In cash movements, the company had a total of -42.31 million as operating cash flow.
Having a look at the company’s valuation, the company is expected to record -1.54 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SURF sounds very interesting.
Is the stock of SURF attractive?
In related news, Chief Medical Officer, ROSS ROBERT W. sold 1,000 shares of the company’s stock in a transaction that recorded on Dec 15. The sale was performed at an average price of 10.48, for a total value of 10,480. As the sale deal closes, the Chief Medical Officer, ROSS ROBERT W. now sold 1,405 shares of the company’s stock, valued at 14,120. Also, Chief Medical Officer, ROSS ROBERT W. sold 595 shares of the company’s stock in a deal that was recorded on Nov 11. The shares were price at an average price of 10.05 per share, with a total market value of 5,980. Following this completion of acquisition, the Chief Medical Officer, ROSS ROBERT W. now holds 4,000 shares of the company’s stock, valued at 40,200. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.50%.
5 out of 6 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Surface Oncology Inc.. 0 analysts has assigned a Sell rating on the SURF stock. The 12-month mean consensus price target for the company’s shares has been set at $13.00.